...
首页> 外文期刊>Surgery today >Management of Hepatic Arterial Infusion Port Following Prophylactic Regional Chemotherapy in Patients who have Undergone Curative Resection of Colorectal Liver Metastases.
【24h】

Management of Hepatic Arterial Infusion Port Following Prophylactic Regional Chemotherapy in Patients who have Undergone Curative Resection of Colorectal Liver Metastases.

机译:接受结直肠癌肝转移根治性切除术的患者在进行预防性区域化学治疗后的肝动脉输注端口管理。

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose. Although hepatic arterial infusion (HAI) is widely performed as a prophylactic chemotherapy for patients who have undergone a curative resection of a metastatic liver tumor from colorectal cancer, the optimal management of implantable ports and catheters after the cessation of such adjuvant therapy remains to be elucidated. Methods. The survival and recurrence rate of 30 patients who received adjuvant regional chemotherapy following a hepatectomy were examined. The outcomes of the 15 patients who were regularly administered heparin into the port to prevent its occlusion were also analyzed. Results. With a median follow-up period of 38.1 months, local recurrence in the residual liver was observed in only 5 patients (17%), and the 3-year hepatic disease-free survival was as high as 82%. Out of the 15 patients who received heparin injection, the ports were successfully maintained in only 6 patients (40%) at from 8.8 to 24.7 months (median, 10.8 months) postoperatively, and 69% of the implantable ports were maintained without occlusion for 12 months. Furthermore, a second course of regional chemotherapy was carried out in only one patient, while a repeat hepatectomy was performed instead of chemotherapy in the other patients with hepatic recurrence. Conclusions. Because HAI remarkably reduced the degree of relapse in the residual liver, there is no benefit in maintaining the port after discontinuing the chemotherapy. Heparin administration via the same port after a cessation of the prophylactic HAI chemotherapy is not justified, and it is desirable to remove the implanted catheter when possible.
机译:目的。尽管已对结直肠癌转移性肝肿瘤进行根治性切除的患者广泛采用肝动脉输注(HAI)作为预防性化学疗法,但仍需阐明停止这种辅助治疗后对可植入端口和导管的最佳管理。方法。检查30例肝切除术后接受辅助区域化疗的患者的生存和复发率。还分析了15例定期将肝素注入港口以防止其阻塞的患者的预后。结果。中位随访期为38.1个月,仅5例患者(17%)观察到残留肝脏局部复发,并且3年无肝病生存率高达82%。在接受肝素注射的15例患者中,只有6例(40%)在术后8.8至24.7个月(中位数为10.8个月)成功地维持了端口,并且69%的可植入端口在没有阻塞的情况下得以维持12个月。几个月。此外,仅在一名患者中进行了第二次区域化疗,而在其他有肝复发的患者中进行了重复肝切除术而不是化疗。结论因为HAI显着降低了残留肝脏的复发程度,所以在停止化疗后维持端口无益处。预防性HAI化疗停止后,通过同一端口进行肝素给药是没有道理的,因此,希望在可能的情况下取出植入的导管。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号